IDEAYA Biosciences, Hengrui Pharmaceuticals, IDE849, SHR-4849, DLL3, Antibody-Drug Conjugate, ADC, Small Cell Lung Cancer, Neuroendocrine Carcinoma, Phase 1 Clinical Trial

South San Francisco, California, United States, October 23, 2026 IDEAYA Biosciences has reported updated Phase 1 results for IDE849...